- Home
- ORIS vs FGEN Comparison
ORIS vs FGEN Comparison
Compare ORIS & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIS
- FGEN
- Stock Information
- Founded
- ORIS 2014
- FGEN 1993
- Country
- ORIS China
- FGEN United States
- Employees
- ORIS N/A
- FGEN N/A
- Industry
- ORIS Farming/Seeds/Milling
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ORIS Consumer Staples
- FGEN Health Care
- Exchange
- ORIS Nasdaq
- FGEN Nasdaq
- Market Cap
- ORIS 40.5M
- FGEN 34.5M
- IPO Year
- ORIS 2024
- FGEN 2014
- Fundamental
- Price
- ORIS $1.52
- FGEN $0.53
- Analyst Decision
- ORIS
- FGEN
- Analyst Count
- ORIS 0
- FGEN 0
- Target Price
- ORIS N/A
- FGEN N/A
- AVG Volume (30 Days)
- ORIS 2.2M
- FGEN 1.7M
- Earning Date
- ORIS 02-21-2025
- FGEN 02-24-2025
- Dividend Yield
- ORIS N/A
- FGEN N/A
- EPS Growth
- ORIS N/A
- FGEN N/A
- EPS
- ORIS 0.43
- FGEN N/A
- Revenue
- ORIS $16,745,999.00
- FGEN $180,015,000.00
- Revenue This Year
- ORIS N/A
- FGEN $21.91
- Revenue Next Year
- ORIS N/A
- FGEN N/A
- P/E Ratio
- ORIS $3.70
- FGEN N/A
- Revenue Growth
- ORIS N/A
- FGEN 16.15
- 52 Week Low
- ORIS $1.16
- FGEN $0.18
- 52 Week High
- ORIS $56.01
- FGEN $2.93
- Technical
- Relative Strength Index (RSI)
- ORIS N/A
- FGEN 51.42
- Support Level
- ORIS N/A
- FGEN $0.52
- Resistance Level
- ORIS N/A
- FGEN $0.61
- Average True Range (ATR)
- ORIS 0.00
- FGEN 0.09
- MACD
- ORIS 0.00
- FGEN -0.01
- Stochastic Oscillator
- ORIS 0.00
- FGEN 17.62
About ORIS Oriental Rise Holdings Limited Ordinary Shares
Oriental Rise Holdings Ltd is a company who is an integrated supplier of tea products in Mainland China. Their major tea products include primarily-processed tea consisting of white tea and black tea, and refined white tea and black tea. Its business operations are vertically integrated, covering cultivation, processing of tea leaves and the sale of tea products to tea business operators (such as wholesale distributors) and end-user retail customers in Mainland China.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.